Revvity (RVTY) Valuation Check After Recent Share Price Gains And Mixed Longer Term Returns

Revvity (RVTY) is drawing attention after recent trading left the stock with a return of about 1.2% over the past day, while performance over the past 3 months remains weaker.

See our latest analysis for Revvity.

At a share price of $88.94, Revvity’s recent 1.2% daily and 2.1% 7 day share price returns contrast with a weaker 30 day share price return of 7.3% and a 1 year total shareholder return decline of 11.5%, suggesting momentum has been fading over a longer horizon as investors reassess both growth potential and risks.

If you are comparing Revvity with other healthcare names using AI in diagnostics and research, it can be useful to scan a wider peer group through 37 healthcare AI stocks

With Revvity trading at $88.94 alongside an indicated discount of about 34% to one analyst price target, the key question for you is simple: is this genuine upside, or is the market already baking in future growth?

Most Popular Narrative: 25.6% Undervalued

Revvity’s fair value in the most followed narrative is set at $119.56, which sits well above the last close at $88.94 and frames a clear valuation gap for investors to assess.

Ongoing shift in product mix toward higher margin, software enabled and consumables driven offerings (e.g., SaaS Signals, reagents, new IDS i20 platform), along with structural cost actions, are expected to materially expand operating and net margins, with 2026 set to start at a higher 28% operating margin baseline.

Read the complete narrative.

Curious what has to happen for that higher margin world to stick? The narrative leans on specific growth rates, profit levels and a valuation multiple that usually belongs to market favorites.

Result: Fair Value of $119.56 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, you still need to factor in risks such as changes to China reimbursement policies and weaker academic or government funding, which could pressure diagnostics volumes and margins.

Find out about the key risks to this Revvity narrative.

Another Angle on Valuation

The narrative and SWS model flag Revvity as trading about 33.8% below an estimated fair value of $134.25, yet the current P/E of 41.5x sits well above both the Life Sciences industry at 33.8x and a fair ratio of 22.6x. This raises the question of whether the stock is mispriced or whether expectations are already rich.

To see how that gap between the current P/E, peers and the fair ratio plays out in practice, take a closer look at the valuation breakdown through See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Feeling mixed after weighing the upside against the concerns raised so far? Act while the details are fresh and weigh both sides through 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Revvity has sharpened your thinking, do not stop here. Broaden your watchlist with other ideas that match your goals and risk comfort.

• Zero in on quality at a discount by checking companies highlighted in the 62 high quality undervalued stocks.
• Explore income potential by scanning companies featured in the 12 dividend fortresses.
• Prioritize resilience by reviewing companies surfaced in the 67 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com